Hawn Dialysis Llc (Jersey City Summit) is a medicare approved dialysis facility center in Jersey City, New Jersey and it has 21 dialysis stations. It is located in Hudson county at 418 Summit Avenue, Jersey City, NJ, 07306. You can reach out to the office of Hawn Dialysis Llc (Jersey City Summit) at (201) 420-8431. This dialysis clinic is managed and/or owned by Davita. Hawn Dialysis Llc (Jersey City Summit) has the following ownership type - Profit. It was first certified by medicare in March, 2017. The medicare id for this facility is 312671 and it accepts patients under medicare ESRD program.
| Name | Hawn Dialysis Llc (Jersey City Summit) |
|---|---|
| Location | 418 Summit Avenue, Jersey City, New Jersey |
| No. of Dialysis Stations | 21 |
| Medicare ID | 312671 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 418 Summit Avenue, Jersey City, New Jersey, 07306 | |
| (201) 420-8431 | |
| Not Available |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago
| NPI Number | 1235504101 |
| Organization Name | Jersey City Summit Dialysis |
| Doing Business As | Hawn Dialysis Llc |
| Address | 414 Summit Ave Jersey City, New Jersey, 07306 |
| Phone Number | (201) 420-8431 |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 7 |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 16 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 68 |
| Percentage of adult patients getting regular hemodialysis at the center | 78 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago
| Adult patients getting regular peritoneal dialysis at the center | 1 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 9 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Hawn Dialysis Llc (Jersey City Summit) with elevated calcium levels.
| Patients with hypercalcemia | 21 |
| Hypercalcemia patient months | 92 |
| Patients with Serumphosphor | 23 |
| Patients with Serumphosphor less than 3.5 mg/dL | 14 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 40 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 17 |
| Patients with Serumphosphor greater than 7 mg/dL | 3 |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 16 |
| Patient months included in arterial venous fistula and catheter summaries | 56 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 77 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
To help reduce COVID-19-related health disparities in vulnerable populations in Texas, a multi-institutional team of researchers led by The University of Texas Health Science Center at Houston will identify disease hotspots and testing deserts in three racially diverse areas, and then develop and evaluate intervention strategies to increase COVID-19 testing.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").
Scientists at Cure Lab, Inc., a biotechnology company based in Canton, Massachusetts, in collaboration with researchers at Boston University and Harvard Medical School have discovered a potential new target for the development of anti-influenza (flu) drugs, including those that may be effective against potentially pandemic influenza strains like H5N1.
A new approach to treating vision loss caused by type 1 Usher syndrome (USH1), the most common condition affecting both sight and hearing, will be unveiled by a scientist at the annual conference of the European Society of Human Genetics tomorrow (Tuesday 3 June).
A Ludwig Cancer Research study has uncovered an entirely novel mechanism by which glioblastoma, the most common kind of brain cancer, evades targeted therapies. Published in the current issue of the journal Science, the paper describes how GBM tumor cells essentially hide the signaling molecule targeted by such therapies, adding a layer of complexity to current models of drug resistance in cancer.
› Verified 4 days ago